In our view, the open issues regarding S1P modulators mainly concerns their positioning within current treatment algorithms, depending on disease location (ileal, ileocolonic or purely colonic involvement) and their potential as combination therapies for the treatment of moderate-to-severe, multi-failure IBD patients [65]. Here, MBTPS1 is linked to inflammatory bowel disease.